Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.84 |
| ▸ | CHAT | P28329 | 2/20 | 0.80 |
| ▸ | EP300 | Q09472 | 4/20 | 0.79 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.79 |
| ▸ | AURKA | O14965 | 2/20 | 0.79 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.79 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL29353902 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL20505754 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL12303241 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL29371268 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL4358590 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL1198 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL219453 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL22277142 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL6382909 | 0.98 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL5497515 | 0.98 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257381-A1 | STEVIA REBAUDIANA KAURENOIC ACID HYDROXYLASE VARIANTS FOR HIGH EFFICIENCY PRODUCTION OF REBAUDIOSIDES | EUAGORE, LLC | 2025-08-14 | — | — | US | disclosed |
| US-12371677-B2 | UDP-dependent glycosyltransferase for high efficiency production of rebaudiosides | CORN PRODUCTS DEVELOPMENT, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240174987-A1 | UDP-DEPENDENT GLYCOSYLTRANSFERASE FOR HIGH EFFICIENCY PRODUCTION OF REBAUDIOSIDES | CORN PRODUCTS DEVELOPMENT, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-115176023-A | Amorpha-4, 11-diene 12-monooxygenase variants and uses thereof | 阿米瑞斯公司 | 2022-10-11 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257381-A1 | STEVIA REBAUDIANA KAURENOIC ACID HYDROXYLASE VARIANTS FOR HIGH EFFICIENCY PRODUCTION OF REBAUDIOSIDES | SPR, ME1, ADH7 | NAA50 2685/4885CHAT 4621/4885EP300 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.